Engineered Probiotics as Tumor-Targeting Drug Factories

Engineered Probiotics as Tumor-Targeting Drug Factories

Scientists from Shandong University, China have developed an innovative cancer treatment strategy by engineering probiotic bacteria to act as tumor-targeting drug producers. In a recent study published in PLOS Biology, researchers modified the well-known probiotic strain Escherichia coli Nissle 1917 (EcN) to synthesize Romidepsin, an FDA-approved anticancer compound.

In mouse models of breast cancer, these engineered bacteria successfully colonized tumor tissue and produced the drug directly at the tumor site. This localized delivery system allowed the treatment to act precisely where it was needed, potentially improving therapeutic effectiveness while minimizing systemic side effects commonly seen in conventional cancer therapies.

Engineered Probiotics as Tumor-Targeting Drug Factories
Image: Freepik

The approach represents a “dual-action” strategy: the bacteria naturally accumulate in tumors, and simultaneously function as in situ drug factories. This combination enhances the anticancer activity of Romidepsin while leveraging the tumor-targeting properties of EcN.

Despite these promising results, the research remains at an early stage. The method has not yet been tested in humans, and key challenges – such as safety, immune responses, and controlled elimination of the bacteria after treatment – must be addressed. If successfully translated, this bacteria-assisted therapy could open a new frontier in targeted cancer treatment.

Research article: Scientists turn probiotic bacteria into tumor-hunting cancer killers

Lambda Biologics’ Oncology Solutions: Patient-derived cancer organoid-based drug evaluation service 

Gastric Cancer Organoid | Breast Cancer Organoid | Hepatocarcinoma Cancer Organoid | Pancreatic Cancer Organoid

>> See more 

Subscribe to the latest updates in the newsletter

Share your disease area, therapeutic candidate and research objectives.

Related Solutions

Organoid Service

Research Service

Technical Service

ODISEI CNS - Human brain & retinal organoid
solutions for translational CNS discovery.

Please provide the information below, and our team will contact you shortly with brochure and relevant case studies.

Thank you for your submission.

Our team has received your request and will get back to you shortly.
If you do not receive our confirmation email, kindly check your spam or junk folder.